LENZ Therapeutics, Inc. (LENZ) EBITDA (2022 - 2023)
LENZ Therapeutics (LENZ) has disclosed EBITDA for 2 consecutive years, with -$23.7 million as the latest value for Q4 2023.
- On a quarterly basis, EBITDA rose 11.48% to -$23.7 million in Q4 2023 year-over-year; TTM through Dec 2023 was -$70.0 million, a 33.77% increase, with the full-year FY2024 number at -$49.6 million, up 29.13% from a year prior.
- EBITDA was -$23.7 million for Q4 2023 at LENZ Therapeutics, down from -$18.9 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$12.7 million in Q1 2023 to a low of -$26.8 million in Q2 2022.